AdaptHealth (NASDAQ:AHCO) Price Target Cut to $14.00 by Analysts at Robert W. Baird

AdaptHealth (NASDAQ:AHCO) had its target price decreased by Robert W. Baird from $16.00 to $14.00 in a research note published on Wednesday morning, Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Separately, Royal Bank of Canada reissued an “outperform” rating and set a $13.00 price objective on shares of AdaptHealth in a report on Monday, August 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $11.36.

AdaptHealth Stock Performance

AHCO stock opened at $10.18 on Wednesday. The firm has a 50 day moving average of $10.74 and a two-hundred day moving average of $10.44. AdaptHealth has a 12 month low of $6.37 and a 12 month high of $11.90. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -1.95, a P/E/G ratio of 1.63 and a beta of 1.11. The company has a quick ratio of 0.94, a current ratio of 1.15 and a debt-to-equity ratio of 1.38.

AdaptHealth (NASDAQ:AHCO) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.02). AdaptHealth had a positive return on equity of 9.58% and a negative net margin of 21.20%. The business had revenue of $805.90 million during the quarter, compared to the consensus estimate of $809.32 million. During the same quarter in the prior year, the company posted $0.19 earnings per share. The company’s revenue for the quarter was up .2% on a year-over-year basis. As a group, equities analysts anticipate that AdaptHealth will post 0.87 EPS for the current fiscal year.

Insider Buying and Selling at AdaptHealth

In other news, COO Shaw Rietkerk sold 25,000 shares of AdaptHealth stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $11.24, for a total value of $281,000.00. Following the transaction, the chief operating officer now directly owns 212,611 shares in the company, valued at approximately $2,389,747.64. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, COO Shaw Rietkerk sold 25,000 shares of the business’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $11.24, for a total transaction of $281,000.00. Following the transaction, the chief operating officer now owns 212,611 shares of the company’s stock, valued at approximately $2,389,747.64. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director David Solomon Williams III sold 4,000 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $11.26, for a total transaction of $45,040.00. Following the completion of the sale, the director now directly owns 36,899 shares of the company’s stock, valued at approximately $415,482.74. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 4.43% of the company’s stock.

Institutional Investors Weigh In On AdaptHealth

A number of institutional investors have recently added to or reduced their stakes in the company. Covestor Ltd raised its holdings in AdaptHealth by 279.6% in the 1st quarter. Covestor Ltd now owns 3,109 shares of the company’s stock valued at $36,000 after acquiring an additional 2,290 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of AdaptHealth during the second quarter valued at approximately $58,000. Blue Trust Inc. acquired a new position in shares of AdaptHealth in the second quarter valued at $85,000. Innealta Capital LLC acquired a new position in shares of AdaptHealth in the second quarter valued at $101,000. Finally, Quest Partners LLC lifted its position in AdaptHealth by 11,522.7% in the second quarter. Quest Partners LLC now owns 10,228 shares of the company’s stock worth $102,000 after purchasing an additional 10,140 shares during the period. 82.67% of the stock is owned by institutional investors and hedge funds.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.